JAZZ vs. RPRX: Jazz Pharmaceuticals vs. Royalty Pharma Stock Comparison
How do Jazz Pharmaceuticals (JAZZ) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Jazz Pharmaceuticals (JAZZ) and Royalty Pharma (RPRX) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
| Profile Item | JAZZ | RPRX |
|---|---|---|
| Name | Jazz Pharmaceuticals plc | Royalty Pharma plc Class A Ordinary Shares |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 15.07 billion USD | 38.70 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2007 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| Total Return (1Y) | 84.44% | 81.08% |
| Total Return (3Y, Annualized) | 27.57% | 39.21% |
| Total Return (5Y, Annualized) | 12.88% | 14.22% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| Volatility (1Y, Annualized) | 38.74% | 22.05% |
| Beta (5Y) | 0.33 | 0.36 |
| Max Drawdown (5Y) | -42.03% | -41.98% |
| Avg. Volume (3M) | 878.80K | 3.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 3.48 |
| Sortino Ratio (1Y) | 4.14 | 5.72 |
Profitability
ROE (TTM)
Royalty Pharma (RPRX) at 12.09% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for RPRX.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.09%
- Max
- 109.18%
- RPRX
- 12.09%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Royalty Pharma (RPRX) at 25.70% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.70%
- RPRX
- 25.70%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.32%
- Max
- 83.12%
- RPRX
- 81.32%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| ROE (TTM) | 5.05% | 12.09% |
| ROA (TTM) | 6.92% | 5.43% |
| Net Margin (TTM) | 4.37% | 25.70% |
| Operating Margin (TTM) | 30.17% | 81.32% |
| Gross Margin (TTM) | 91.10% | 99.79% |
Growth
Revenue Growth
Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Royalty Pharma (RPRX) at 23.09% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| Revenue Growth (YoY) | 4.88% | 5.06% |
| Revenue Growth (3Y CAGR) | 5.26% | 2.06% |
| EPS Growth (YoY) | -167.51% | 23.09% |
| EPS Growth (3Y CAGR) | -- | 161.10% |
Financial Strength
Current Ratio (MRQ)
Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.29
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- RPRX
- 1.29
- Min
- 0.10
Debt / Equity (MRQ)
Both Jazz Pharmaceuticals (JAZZ) at 1.35 and Royalty Pharma (RPRX) at 0.88 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.88
- Max
- 1.42
- RPRX
- 0.88
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 1.29 |
| Debt / Equity (MRQ) | 1.35 | 0.88 |
| Net Debt / EBITDA | 1.39 | 4.76 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.37%
- RPRX
- 1.37%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.46%
- RPRX
- 60.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.37% |
| Dividend Payout Ratio (TTM) | 0.00% | 60.46% |
Valuation
P/E Ratio (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 69.46 and Royalty Pharma (RPRX) at 43.99 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.99
- Max
- 85.34
- RPRX
- 43.99
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.79
- Max
- 58.18
- Q3
- 25.77
- RPRX
- 14.79
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and Royalty Pharma (RPRX) at 4.39 are valued close to their industries’ norm against book — neither stands out from peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.39
- Max
- 13.53
- Q3
- 6.54
- RPRX
- 4.39
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | JAZZ | RPRX |
|---|---|---|
| P/E Ratio (TTM) | 69.46 | 43.99 |
| P/S Ratio (TTM) | 3.19 | 14.79 |
| P/B Ratio (MRQ) | 3.59 | 4.39 |
| Free Cash Flow Yield (TTM) | 11.16% | -1.16% |